Peter Ravdin, MD, PhD, discusses the differences between anthracycline and nonanthracycline chemotherapy regimens and how to best communicate these differences in treatment choices to patients with breast cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the relative merits of anthracycline-based chemotherapy and nonanthracycline-based therapy to patients with breast cancer
- Discuss with patients how estrogen receptor status, progesterone receptor status, and HER2 status relates to breast cancer outcomes
- Describe key findings of breast cancer trials demonstrating patient responses to anthracycline or nonanthracyline-based regimens